Our #ASCO25 paper Scoring approach 1st of kind predicting #clinicaltrial outcomes: https://t.co/A4n0QMfPrF using #NGS +drug targeting profile, found patients who didn’t have prominent markers, YET did fairly well. For treatment planning & to qualify/quantify known+ novel drugs

Our system quantifies the assessment for each patient with a score. This molecular matching score can be used for trial planning, rescue, optimization, matching, and real world retrospective data analysis.

We can simulate in-silico trials based in molecular profiling of patients’ cancers. We use NGS testing as input & can predict who will do better or worse on any given drug or combination, including novel agents. Agnostic to platform & can optionally include multi-omics.

@VivekSubbiah @YLeyfman @weldeiry @DrChoueiri @chadinabhan @neerajaiims @PGrivasMDPhD @SewantiLimaye @DrYukselUrun @BenWestphalen @GlopesMd We agree @VivekSubbiah that #NGS should be standard of care! The lab output is our input @CureMatch #precisiononcology #ArtificialInteligence #precisionmedicine

Important to read!

🎉🚨 Hot off the press! Congrats to @JCOOP_ASCO on their 20th anniversary! With #ASCO25 @ASCO behind us, perfectly timed for #EHA2025 👉 Delighted to share our Policy & Practice paper on "Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare

@oncodaily @OncoAlert @ASCO

#clinicaltrials take ten years and cost $2 billion on average, with the patient recruitment bottleneck representing roughly 35% of that. More optimal tools for patient stratification & matching can accelerate this process and help get the treatments to #patients faster.

@PTrubey Thank you for the advocacy@PTrubey! On average about 5 mutations for each of the roughly 700 #Cancers identified, and 300 drugs…that’s over a trillion patterns! Beyond human cognition & where our KRR #AI is helpful. #precisiononcology

@chamath @cascapital @OrbiMed @PfizerOncMed @Novartis @biogen

Use of an in-silico clinical trial intelligence solution to predict outcomes of tinengotinib, a potent multi-kinase small molecule FGFR inhibitor in patients with cholangiocarcinoma, based on the molecular matching score. https://t.co/IbuLoQkf2X

@PeterDiamandis @weldeiry

@Dr_R_Kurzrock @SyneosHealth @TransThera @ASCO #Cholangiocarcinoma @curecc

@Dr_R_Kurzrock @SyneosHealth @TransThera @ASCO

Thank you to our incredible team, our founder @Dr_R_Kurzrock, @SyneosHealth & Dr. Harb, @TransThera @ASCO

Many of these drugs require molecular testing to identify patients who may benefit from them. How can we expect #oncologists to keep up without the benefit of technology or automated tools?

Without tools to standardize how testing and treatment should occur, doctors in those settings can quickly become overwhelmed by the vast number of new testing and treatment options. Over the last 5 years there have been around many new cancer medications introduced in the US.

80% of American cancer patients are treated in the community setting where oncologists see dozens of patients a day, each with a unique history, health background and tumor type.

Every individual cancer patient has unique biomarkers that can inform which precision oncology treatments and therapies are appropriate and which are not.

@Dr_R_Kurzrock This is where a @curematch report can be critical to account for multiple tumor pathways, some of which could lead to hyper-progression if not factored into treatment selection.